Session 104
Partnering for Patient Impact

Patients have always been an important part of developing new drugs and treatments. Now patient centricity is increasing with companies hiring chief patient experience officers and partnering to integrate patient centricity into all aspects of the business. Organizations are being structured to put the patient needs at the forefront in academic collaborations, clinical trials, and patient support services.

What does an increasingly patient centric organization mean to alliance management professionals? How will this shape, and reshape biopharma alliances? Will patient centricity change how drugs and treatments are developed within a collaborative ecosystem?

This interactive panel session will give you insights on:


Christine A. Carberry, CSAP
Carberry Consulting

Christine Carberry is a biopharmaceutical leader with the unique ability to transform strategy into results through the power of collaboration. Most recently she was the Chief Operating Officer at Keryx Biopharmaceuticals. In her leadership role she served on the Executive Committee while leading initiatives in cross-functional integration, operational excellence, and program management. She headed the Manufacturing, Technical Operations, Quality, Human Resources, and Regulatory functions.

Prior to Keryx, she served as a Senior Vice President at Forum Pharmaceuticals. At Forum, She established the Program & Alliance Management cross-functional matrix to integrate across the entire organization. She also led the CMC, Supply Chain, and Quality functions.

At Biogen for over 25 years, Christine held positions of increasing responsibility as the company advanced from a biotechnology pioneer to an internationally recognized Fortune 500 company.

Christine is a Certified Strategic Alliance Professional (CSAP). She holds an M.S. in innovation and technology management from Boston University, Graduate Certificates in Management and Biotechnology Strategy from Harvard University, and a B.S. in biochemistry from the University of New Hampshire.


Chandra Ramanathan, PhD
Global Head, Pharma R&D Open Innovation

Chandra Ramanathan, Global Head of Pharma R&D Open Innovation, leads the Open Innovation Centers (OICs) around the world (US, Europe, Japan, China and Singapore). The OICs focus on early access to breakthrough technologies, management of strategic alliances, and public private partnerships.

Chandra's previous roles at Bayer include Head of Open Innovation Center North America-East, Global Program Lead for External Innovation/Life Sciences, Global Launch Team Leader (copanlisib) and Head of Global Oncology Pipeline Marketing.

Prior to joining Bayer, Chandra worked at Wyeth (Pfizer) and Bristol-Myers Squibb in various roles in Drug Discovery, Applied Genomics, and Business Development & Licensing.

Chandra earned an MBA from the Columbia Business School, a PhD in Genomics/ Bioinformatics, an MS in Medicinal Chemistry, and a BS in Pharmacy.

Chandra is an adjunct assistant professor at the Tufts School of Medicine and is on the Board of Directors of MassBIO, the Massachusetts Biotech Council.

Jeremy Ahouse, CSAP, PhD
Vice President, Alliances
Merus, N.V.

Merus (, a clinical-stage immuno-oncology company develops therapeutics with the goal of treating and curing serious illnesses. Merus' Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains against virtually any target. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies, using our Biclonics® and Triclonics® platforms.

Jeremy is responsible for establishing Merus' alliance function and managing a broad research and clinical collaboration with current (e.g., Incyte, Lilly/Loxo, Simcere, Betta) and future partners. Jeremy has worked in pharmaceutical and biotech research and clinical collaborations with Celgene, Novartis, ImmunoGen, Vantage Partners, and Millennium.

Jeremy served on the board of the Association of Strategic Alliance Partners (ASAP) and helped to establish their CAAM and CSAP certification exams and contributed to the ASAP best practices guide. He serves on the leadership team of the NE ASAP chapter.

He earned his PhD in immunology and biophysics, and held an HHMI post-doc in Developmental Genetics. He trained as a mediator and negotiator at Harvard's Program on Negotiation and has a keen interest in multi-party agreements and in how working together helps research and drug development by improving how we come to do research and development together–the epistemology of collaboration.

Mark Coflin, CSAP
Vice President, Head Global Alliance Management
Simcere Pharmaceutical Group